Spinocerebellar ataxia (SCA) is a neurodegenerative disorder ... treatment for polyglutamine diseases in humans through a ...

Additionally, we cover the landscape of Spinocerebellar Ataxia clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Spinocerebellar Ataxia ...

(1 Trusted Source New Drug Candidate for Spinocerebellar Ataxia ~Clinical Trial Results of L-Arginine for Spinocerebellar Ataxia Type 6~ Go to source). Spinocerebellar ataxia (SCA ...

The report provides a detailed analysis of the current spinocerebellar ataxia marketed drugs and late-stage pipeline drugs, ...

has announced plans to conduct a registrational clinical trial evaluating its investigational therapy, SLX-100, for spinocerebellar ataxia type 27B (SCA27B). This pivotal-powered study will be funded ...

Background of the Study Spinocerebellar ataxia (SCA) is a neurodegenerative ... for polyglutamine diseases in humans through a clinical trial. This study (AJA030-002, jRCT2031200135) was designed ...

The Spinocerebellar Ataxia pipeline is advancing fast as troriluzole nears FDA nod and rivals race with gene and stem cell therapies to seize market edge. Disease modification in spinocerebellar ...

According to Biohaven, the FDA’s decision on the NDA is expected during the 3rd quarter of 2025. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...

Based on a clinical trial design and endpoints that ... and positive results in the treatment of the neurological disease spinocerebellar ataxia (SCA). Troriluzole is a prodrug, a compound that ...